Keliximab (SB-210396) is a chimeric human/macaque IgG1 anti-CD4 monoclonal antibody with a Ki value of 1.0 nM for soluble CD4. Keliximab blocks T cell proliferation and inhibits IL-2 production. Keliximab can be used for cancer research.
Keliximab shows a Kd value of 1.0 nM for binding with soluble CD4 (sCD4)[2].Keliximab (0.01-10 μg/mL; 30 min) dose-dependently binds to the CD4+ tmoma cell line SupT1 with an ED50 of 0.2 μg/mL[1].Keliximab (0-1000 ng/mL) blocks T cell proliferation and IL-2 production with IC50s of 10-30 ng/mL in primary human plasmablastic lymphomas (PBLs)[1].Keliximab (1-1000 ng/mL; 5 min) dose-dependently mediates cell-cell adhesion with an ED50 value of 20 ng/mL[1].
Keliximab (5-125 mg/kg; i.v., once) decreases CD4+ T cells[1].
References:
[1]. Sharma A, et al. Comparative pharmacodynamics of keliximab and clenoliximab in transgenic mice bearing human CD4. J Pharmacol Exp Ther. 2000 Apr;293(1):33-41.
[2]. Anderson D, et al. A primatized MAb to human CD4 causes receptor modulation, without marked reduction in CD4+ T cells in chimpanzees: in vitro and in vivo characterization of a MAb (IDEC-CE9.1) to human CD4. Clin Immunol Immunopathol. 1997 Jul;84(1):73-84.